United States

EyePoint Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

EyePoint Pharmaceuticals Announces Proposed Public Offering

Lead Product(s): Dexamethasone

Therapeutic Area: Trauma (Emergency, Injury, Surgery)

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Guggenheim Securities

Deal Size: $21.7 million Upfront Cash: Undisclosed

Deal Type: Public Offering February 20, 2020

Details:

EyePoint intends to use the net proceeds of the offering to continue to fund the commercialization and expand the access of DEXYCU® and YUTIQ® and for general corporate purposes.

EyePoint Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

EyePoint Pharmaceuticals and Vision Center Network Ink Agreement

Lead Product(s): Dexamethasone

Therapeutic Area: Trauma (Emergency, Injury, Surgery)

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Vision Center Network of America

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement February 18, 2020

Details:

The agreement will enable VCNA physicians to incorporate DEXYCU into their surgical protocols for treating ocular inflammation associated with cataract surgery.